LGND

Ligand Pharmaceuticals Incorporated [LGND] Stock Forecast

Q: What is Ligand Pharmaceuticals Incorporated stock symbol ?

Ligand Pharmaceuticals Incorporated is a US stock, located in Emeryville of Ca and trading under the symbol LGND

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

LGND Stock Summary

EPS has increased from the previous year and become positive (Yearly statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Earnings are expected to fall -100% next year

Profit margins (0.11%) are lower than the previous year (0.4%)

Top 10 Correlated ETFs

LGND

Top 10 Correlated Stocks

LGND

In the News

LGND Financial details

Company Rating

Buy

Market Cap

1.44B

Income

49.64M

Revenue

131.31M

Book val./share

40.13

Cash/share

9.75

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

75.48

Forward P/E

PEG

-0.73

P/S

8.34

P/B

1.92

P/C

7.32

P/FCF

14.35

Quick Ratio

12.17

Current Ratio

13.66

Debt / Equity

0.01

LT Debt / Equity

0.01

EPS (TTM)

2.89

EPS next Y

EPS next Q

EPS this Y

-1074.19%

EPS next Y

EPS next 5Y

EPS last 5Y

-38.06%

Revenue last 5Y

1.77%

Revenue Q/Q

-14.5%

EPS Q/Q

-240.54%

SMA20

8.33%

SMA50

SMA100

34.48%

Inst Own

70.49%

Inst Trans

0.78%

ROA

ROE

ROC

-0.01%

Gross Margin

80%

Oper. Margin

-5%

Profit Margin

11%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

49.24-94.57

52W High

-24.09%

52W Low

+45.63%

RSI

Rel Volume

0.09

Avg Volume

164.99K

Volume

15.12K

Perf Week

-12.37%

Perf Month

-3.27%

Perf Quarter

43.96%

Perf Half Y

27.07%

Beta

0.921

Volatility

3.96%, 3.92%

Prev Close

-1.6%

Price

71.36

Change

-9.33%

LGND Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	6.33	11.52	16.66	11.63	7.59
Net income per share	33.13	-0.18	3.44	-0.31	3.02
Operating cash flow per share	-1.54	3.37	4.74	8.17	2.87
Free cash flow per share	-1.68	3.1	4.21	7.11	-0.25
Cash per share	56.32	25.41	20.51	0.01	9.85
Book value per share	40.39	43.84	49.41	35.42	40.52
Tangible book value per share	23.24	-5.34	4.6	8.25	13.42
Share holders equity per share	40.39	43.84	49.41	35.42	40.52
Interest debt per share	36.11	29.78	21.35	5.31	0.39
Market cap	1.98B	1.61B	2.57B	1.13B	1.24B
Enterprise value	1.62B	2.02B	2.89B	1.21B	1.22B
P/E ratio	3.15	-539.23	44.96	-215.9	23.69
Price to sales ratio	16.47	8.63	9.27	5.74	9.41
POCF ratio	-67.53	29.49	32.6	8.17	24.92
PFCF ratio	-62.12	32.11	36.68	9.4	-289.19
P/B Ratio	2.58	2.27	3.13	1.89	1.76
PTB ratio	2.58	2.27	3.13	1.89	1.76
EV to sales	13.45	10.82	10.41	6.19	9.28
Enterprise value over EBITDA	-2.01	63.03	24.62	139.05	23.79
EV to operating cash flow	-55.17	36.94	36.62	8.81	24.58
EV to free cash flow	-50.75	40.23	41.2	10.13	-285.26
Earnings yield	0.32	0	0.02	0	0.04
Free cash flow yield	-0.02	0.03	0.03	0.11	0
Debt to equity	0.85	0.64	0.41	0.15	0.01
Debt to assets	0.44	0.33	0.26	0.12	0.01
Net debt to EBITDA	0.45	12.72	2.7	10.04	-0.33
Current ratio	66.09	5	11.15	2.67	14.15
Interest coverage	-0.16	0.31	4.21	-14.18	14.97
Income quality	-0.05	-18.29	1.38	-4.13	0.95
Dividend Yield	0	0	0.01	0	0
Payout ratio	0	-1.01	0.27	-0.96	0
Sales general and administrative to revenue	0.35	0.35	0.21	0.36	0.4
Research and developement to revenue	0.46	0.32	0.25	0.18	0.19
Intangibles to total assets	0.22	0.58	0.57	0.6	0.56
Capex to operating cash flow	0.09	-0.08	-0.11	-0.13	-1.09
Capex to revenue	-0.02	-0.02	-0.03	-0.09	-0.41
Capex to depreciation	-0.06	-0.16	-0.17	-0.35	-1.51
Stock based compensation to revenue	0.2	0.16	0.14	0.31	0.2
Graham number	173.52	13.49	61.8	15.7	52.43
ROIC	0	0	0.08	0.01	0.01
Return on tangible assets	0.55	-0.01	0.1	-0.02	0.14
Graham Net	21.2	-11.37	-3.38	-7.83	4.69
Working capital	1.11B	400.45M	423.09M	164.79M	220.65M
Tangible asset value	441.47M	-86.45M	76.52M	139.18M	232.09M
Net current asset value	421.57M	-152.2M	-15M	98.42M	106.72M
Invested capital	0.85	0.64	0.41	0.15	0.01
Average receivables	48.8M	50.41M	75.36M	63.34M	37.18M
Average payables	12.9M	3.1M	6.09M	4.2M	7.45M
Average inventory	7.21M	16.89M	26.91M	20.31M	18.63M
Days sales outstanding	126.69	115.64	120.7	65.17	109.27
Days payables outstanding	77.84	45.4	49.33	0.04	470.23
Days of inventory on hand	234.69	317.82	160.42	91.85	756.74
Receivables turnover	2.88	3.16	3.02	5.6	3.34
Payables turnover	4.69	8.04	7.4	9.95K	0.78
Inventory turnover	1.56	1.15	2.28	3.97	0.48
ROE	0.82	0	0.07	-0.01	0.07
Capex per share	-0.13	-0.28	-0.53	-1.06	-3.11

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	2.98	2.58	1.53	1.89	1.61
Net income per share	-0.86	2.46	0.13	-0.74	1.04
Operating cash flow per share	3.17	1.99	0	0.44	0.46
Free cash flow per share	3.1	1.85	-0.02	0.41	-2.44
Cash per share	0.01	27.93	23.71	10.96	9.75
Book value per share	35.38	37.88	38.49	38.29	40.13
Tangible book value per share	8.24	11.5	12.91	13.82	13.29
Share holders equity per share	35.38	37.88	38.49	38.29	40.13
Interest debt per share	5.2	5.27	0.79	0.36	0.36
Market cap	1.13B	1.26B	1.25B	1.04B	1.25B
Enterprise value	1.22B	1.06B	1.04B	1.03B	1.23B
P/E ratio	-19.41	7.48	135.98	-20.35	17.15
Price to sales ratio	22.39	28.54	47.24	31.68	44.39
POCF ratio	21.1	36.97	-15.19K	136.2	154.67
PFCF ratio	21.57	39.8	-4.37K	145.47	-29.23
P/B Ratio	1.89	1.94	1.87	1.57	1.78
PTB ratio	1.89	1.94	1.87	1.57	1.78
EV to sales	24.13	24.13	39.38	31.29	43.79
Enterprise value over EBITDA	-21.79	-63.21	404.77	43.84	124.63
EV to operating cash flow	22.74	31.26	-12.66K	134.51	152.59
EV to free cash flow	23.25	33.65	-3.64K	143.66	-28.83
Earnings yield	-0.01	0.03	0	-0.01	0.01
Free cash flow yield	0.05	0.03	0	0.01	-0.03
Debt to equity	0.15	0.14	0.02	0.01	0.01
Debt to assets	0.12	0.11	0.02	0.01	0.01
Net debt to EBITDA	-1.57	11.55	-80.85	-0.55	-1.7
Current ratio	2.67	3.32	9.42	13.66	14.15
Interest coverage	-35.15K	11.89	-0.97	122	-25.63
Income quality	-3.06	0.81	-0.04	-0.74	0.44
Dividend Yield	0	0	0.01	0	0
Payout ratio	-0.36	0.12	3.96	0	0
Sales general and administrative to revenue	0.62	0.25	0.43	0.45	0.57
Research and developement to revenue	0.18	0.15	0.26	0.17	0.2
Intangibles to total assets	0.6	0.55	0.58	0.55	0.56
Capex to operating cash flow	-0.02	-0.07	2.48	-0.06	-6.29
Capex to revenue	-0.02	-0.05	-0.01	-0.01	-1.81
Capex to depreciation	-0.11	-0.26	-0.02	-0.06	-5.69
Stock based compensation to revenue	0.58	0.13	0.27	0.21	0.2
Graham number	26.17	45.77	10.71	25.18	30.66
ROIC	0.02	0.01	0	0	-0.01
Return on tangible assets	-0.05	0.12	0.01	-0.04	0.05
Graham Net	-7.82	19.97	20.31	7.41	4.64
Working capital	164.79M	229.27M	247.32M	238.9M	220.65M
Tangible asset value	139.18M	196.3M	223.06M	240.19M	232.09M
Net current asset value	98.42M	163.44M	183.5M	153.95M	106.72M
Invested capital	0.15	0.14	0.02	0.01	0.01
Average receivables	50.5M	32.11M	28.59M	33.59M	39.25M
Average payables	17.62M	3.07M	11.5M	14.99M	14M
Average inventory	17.81M	13.65M	20.46M	26.15M	24.68M
Days sales outstanding	62.59	59.73	95.56	107.3	125.91
Days payables outstanding	0.02	148.55	909.87	338.57	805.56
Days of inventory on hand	55.36	339.25	1.45K	655.75	1.3K
Receivables turnover	1.44	1.51	0.94	0.84	0.71
Payables turnover	4.07K	0.61	0.1	0.27	0.11
Inventory turnover	1.63	0.27	0.06	0.14	0.07
ROE	-0.02	0.06	0	-0.02	0.03
Capex per share	-0.07	-0.14	-0.01	-0.03	-2.91

LGND Frequently Asked Questions

What is Ligand Pharmaceuticals Incorporated stock symbol ?

Ligand Pharmaceuticals Incorporated is a US stock , located in Emeryville of Ca and trading under the symbol LGND

What is Ligand Pharmaceuticals Incorporated stock quote today ?

Ligand Pharmaceuticals Incorporated stock price is $71.36 today.

Is Ligand Pharmaceuticals Incorporated stock public?

Yes, Ligand Pharmaceuticals Incorporated is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 164.99K
Market Capitalization 1.44B
Employee 58
CEO Mr. Scott M. Plesha
Headquarters EmeryVille,CA,US
IPO Date 1992-11-18
Website https://www.ligand.com

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.